Wedbush maintains Beam Therapeutics at Outperform, raises price target to $33 from $30
Wedbush reaffirmed its Outperform rating for Beam Therapeutics and increased its price target to $33 from $30, suggesting a 31.2% upside from the Nov 10 close of $25.15. Recent analyst price targets for the company range from $30 to $80.
How this was made

The 30-second read
Why it matters
For traders, the actionable element is the incremental sentiment from the target raise, but the lack of new company-specific information limits conviction.
Market read
This is primarily a sentiment/expectations update rather than a new fundamental catalyst.
What to watch
The article does not state the thesis behind the target change, nor does it provide any new clinical, regulatory, or financial datapoint that would justify a durable repricing.
Background
The piece is a sell-side update: Wedbush maintained an Outperform rating and increased its Beam Therapeutics price target.
Ticker impact
Wedbush maintained Beam Therapeutics at Outperform and raised its price target to $33 from $30, implying upside versus the Nov 10 close.
Mild upward bias as traders price in improved sell-side expectations, with limited follow-through unless new clinical or financial data emerges.
The article contains only an analyst rating and price-target change, plus implied upside math, with no new trial, regulatory, or company-specific operational disclosure.
Market effects
Small read-through for biotech sentiment, but no sector-wide policy or data catalyst is provided.
No specific regional market linkage beyond general biotech risk appetite.
Limited global relevance since the update is a single-name analyst target change.
Counterpoint
Price-target increases can lag or reverse if subsequent trial readouts or financing needs disappoint, so the move may fade without new fundamentals.
Key entities
- companyBeam Therapeutics
Subject of the analyst rating and price-target change described in the article.
- analyst_firmWedbush
Brokerage issuing the Outperform maintenance and raised price target.
